Ascendis Pharma A/S $ASND Position Reduced by Sterling Capital Management LLC

Posted by Brenda Bartman on Jun 28th, 2026

Sterling Capital Management LLC trimmed its position in Ascendis Pharma A/S (NASDAQ:ASND – Free Report) by 39.8% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 14,929 shares of the biotechnology company’s stock after selling 9,880 shares during the period. Sterling Capital Management LLC’s holdings in Ascendis Pharma A/S were worth $3,415,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Cetera Investment Advisers acquired a new stake in shares of Ascendis Pharma A/S in the second quarter valued at $552,000. Rhumbline Advisers raised its position in Ascendis Pharma A/S by 4.0% in the second quarter. Rhumbline Advisers now owns 1,441 shares of the biotechnology company’s stock worth $249,000 after acquiring an additional 55 shares in the last quarter. Daiwa Securities Group Inc. lifted its holdings in Ascendis Pharma A/S by 66.2% in the 2nd quarter. Daiwa Securities Group Inc. now owns 3,737 shares of the biotechnology company’s stock valued at $645,000 after acquiring an additional 1,488 shares during the last quarter. Qube Research & Technologies Ltd lifted its holdings in Ascendis Pharma A/S by 83.4% in the 2nd quarter. Qube Research & Technologies Ltd now owns 201,044 shares of the biotechnology company’s stock valued at $34,700,000 after acquiring an additional 91,412 shares during the last quarter. Finally, Squarepoint Ops LLC bought a new position in shares of Ascendis Pharma A/S during the 2nd quarter valued at about $897,000.

Insider Activity at Ascendis Pharma A/S

In related news, Director Jean Jacques Bienaime acquired 400 shares of the company’s stock in a transaction on Tuesday, May 26th. The shares were purchased at an average price of $237.80 per share, for a total transaction of $95,120.00. Following the purchase, the director owned 400 shares in the company, valued at $95,120. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Flemming Steen Jensen sold 19,460 shares of the stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $238.49, for a total transaction of $4,641,015.40. The disclosure for this sale is available in the SEC filing. Company insiders own 40.00% of the company’s stock.

Ascendis Pharma A/S Stock Down 0.3%

Shares of Ascendis Pharma A/S stock opened at $260.75 on Friday. Ascendis Pharma A/S has a 1 year low of $160.86 and a 1 year high of $271.89. The company has a market cap of $16.27 billion, a P/E ratio of 30.08 and a beta of 0.39. The company has a current ratio of 1.00, a quick ratio of 0.72 and a debt-to-equity ratio of 0.79. The stock has a 50-day moving average price of $232.43 and a 200 day moving average price of $225.66.

Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) last released its earnings results on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.21 by $0.11. The business had revenue of $285.45 million for the quarter, compared to analysts’ expectations of $362.47 million. As a group, analysts expect that Ascendis Pharma A/S will post 4.55 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently commented on ASND shares. Royal Bank Of Canada boosted their target price on shares of Ascendis Pharma A/S from $250.00 to $275.00 and gave the stock an “outperform” rating in a report on Monday, March 2nd. Wall Street Zen cut shares of Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. Wells Fargo & Company decreased their price target on shares of Ascendis Pharma A/S from $330.00 to $326.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Wolfe Research reaffirmed an “outperform” rating and issued a $260.00 price target on shares of Ascendis Pharma A/S in a report on Monday, March 2nd. Finally, Stifel Nicolaus set a $332.00 price objective on Ascendis Pharma A/S in a research report on Wednesday, March 4th. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $295.39.

View Our Latest Stock Analysis on Ascendis Pharma A/S

Ascendis Pharma A/S Profile

(Free Report)

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.